Glibenclamide and glipizide in maturity onset diabetes. A double-blind cross-over study.
The effects of glibenclamide and glipizide on the concentrations of S-glucose, S-insulin and S-lipids and on the 24-hour urinary glucose excretion were studied in 37 patients with maturity onset diabetes. A double-blind, cross over double-dummy technique was used. The fasting S-insulin concentration was higher during glibenclamide therapy, while the increase in insulin concentration one hour postprandially was stronger during  glipizide therapy, supporting the concept that glibenclamide has a more prolonged and glipizide a more fast-acting effect on insulin secretion. The S-glucose concentration was lower in the fasting state as well as one hour postprandially during glibenclamide therapy which, together with a lower 24-hour urinary glucose excretion, indicates that glibenclamide has a stronger blood glucose-lowering effect. Although statistically significant, the differences were marginal from a clinical point of view. The lipid levels remained unchanged.
D000368:Aged; D001786:Blood Glucose / Q000032:analysis; D002986:Clinical Trials as Topic; D003920:Diabetes Mellitus / Q000188:drug therapy*; D004311:Double-Blind Method; D005260:Female; D005913:Glipizide / Q000627:therapeutic use*; D005905:Glyburide / Q000627:therapeutic use*; D006801:Humans; D007328:Insulin / Q000032:analysis; D008055:Lipids / Q000032:analysis; D008297:Male; D008875:Middle Aged; D010919:Placebos; D011897:Random Allocation; D013453:Sulfonylurea Compounds / Q000627:therapeutic use*
D001786:Blood Glucose; D007328:Insulin; D008055:Lipids; D010919:Placebos; D013453:Sulfonylurea Compounds; D005905:Glyburide; D005913:Glipizide